We therefore treated SPC-A1 cells with different concentrations of carboplatin (CBP) and found that the IC50 values of the ANKRD29 overexpressed group were significantly lower than control group (Fig. 5G), indicating that ANKRD29 might regulate the drug sensitivity of NSCLC cells to CBP. The gene discussed is ANKRD29; the disease is non-small cell lung carcinoma.